Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -36.55% is 17% above its 1-year average of -44.22%, near the high end of its 1-year range (-51.88%–-36.55%).
As of the fiscal period ended Wednesday, December 31, 2025. 17.34% above its 12-month average of -44.22%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -16.12%.
RETURN ON ASSETS (ROA)
-36.55%
RETURN ON ASSETS (ROA) AVG TTM
-44.22%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+17.34%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.02%
median of 551 covered companies
CURRENT VS SECTOR MEDIAN
-30.44%
vs the sector median at left
Attovia Therapeutics, Inc.
Market Cap
$762.06M
Return on Assets (ROA)
-36.55%
TTM Avg
-44.22%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$770.34M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
Market Cap
$772.90M
Return on Assets (ROA)
-24.44%
TTM Avg
-47.18%
3Y Avg
-56.01%
5Y Avg
-52.81%
Market Cap
$773.03M
Return on Assets (ROA)
-13.47%
TTM Avg
-22.22%
3Y Avg
-41.40%
5Y Avg
-40.82%
Market Cap
$788.35M
Return on Assets (ROA)
1.14%
TTM Avg
0.56%
3Y Avg
-13.91%
5Y Avg
-9.14%
Market Cap
$796.60M
Return on Assets (ROA)
-5.26%
TTM Avg
0.19%
3Y Avg
-3.34%
5Y Avg
-3.22%
Market Cap
$759.16M
Return on Assets (ROA)
-32.91%
TTM Avg
-25.26%
3Y Avg
-23.04%
5Y Avg
-20.66%
Market Cap
$748.37M
Return on Assets (ROA)
-42.53%
TTM Avg
-41.06%
3Y Avg
-49.54%
5Y Avg
-47.47%
Market Cap
$808.29M
Return on Assets (ROA)
-8.70%
TTM Avg
6.33%
3Y Avg
-16.09%
5Y Avg
-46.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $762.06M | -36.55% | -44.22% | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $770.34M | -18.03% | -7.81% | -4.40% | -1.35% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $772.90M | -24.44% | -47.18% | -56.01% | -52.81% |
| Geron Corporation (GERN)vs › | $773.03M | -13.47% | -22.22% | -41.40% | -40.82% |
| Mesa Laboratories, Inc. (MLAB)vs › | $788.35M | 1.14% | 0.56% | -13.91% | -9.14% |
| AdaptHealth Corp. (AHCO)vs › | $796.60M | -5.26% | 0.19% | -3.34% | -3.22% |
| Design Therapeutics, Inc. (DSGN)vs › | $759.16M | -32.91% | -25.26% | -23.04% | -20.66% |
| Candel Therapeutics, Inc. (CADL)vs › | $748.37M | -42.53% | -41.06% | -49.54% | -47.47% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | -8.70% | 6.33% | -16.09% | -46.82% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $731.98M | -20.44% | -45.26% | -91.41% | -102.66% |
ROA
-36.5%
ROE
-40.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -36.55% |
| 2024-12-31 | -51.88% |
